[Home] [Headlines] [Latest Articles] [Latest Comments] [Post] [Sign-in] [Mail] [Setup] [Help]
Status: Not Logged In; Sign In
Health See other Health Articles Title: The Drug That Could Reverse Alzheimer's A drug in early animal trials has shown promising results, appearing to reverse the symptoms of Alzheimers disease in mice. Additionally, in mice, the treatment reduced inflammation in parts of the brain that are associated with memory and learning, according to a study led by Susan Farr of Saint Louis University School of Medicine, published in the Journal of Alzheimers Disease. READ MORE A Runners Guide to Hydration The mice were engineered to produce a mutant form of human beta amyloid, one of the proteins associated with Alzheimers disease. In a previous study, the researchers had tested mice that naturally overproduced mouse beta amyloid; this step was to see if the drug would work with the human version. Both types of mice showed impaired learning as they aged, much like humans with Alzheimers disease. Two groups of mice were tested: the mutants, and wild-type mice. The wild-type mice were given random compounds, along with half of the mutants. The other half of the mutants received the experimental drug, called antisense oligonucleotide or OL-1. They were then tested in mazes, to see how well they learned and remembered while exploring a new location, and in recognizing objects. The genetically engineered mice that received OL-1 did about as well as the wild mice. READ MORE Antibacterial Soaps Deadly Secret It reversed learning and memory deficits and brain inflammation in mice that are genetically engineered to model Alzheimers disease, Farr said in a statement released by the school. Our current findings suggest that the compound is a potential treatment for Alzheimers disease. About 5 million Americans who are 65 or older have Alzheimers disease now, and that number may rise to 16 million in 2050, according to the Alzheimers Association, an advocacy organization for the disease. There is no cure. READ MORE MRSA Isnt the Real Problem With E-Cigs Four drugs are currently used in Alzheimers disease: Aricept, Exelon, Reminyl, and Namenda. They all temporarily treat symptoms of memory loss, but lose effectiveness as the disease progresses. Unlike these drugs, OL-1 doesnt target symptoms. Its molecules bind to messenger RNA, allowing certain genes to be turned off. Here, the blockage of RNA prevents extra amyloid from being produced by targeting its precursor protein and making less of it. The hope is that by lowering the amount of amyloid, fewer mind-robbing plaques would appeareither slowing the diseases progression or halting it entirely. READ MORE Choose the Right Probiotic for You OL-1 hasnt been through the toxicity trials needed to determine if its safe for human use. Many promising treatments for diseases dont make it past this step into Phase 1 testing in humans. And even thats just the beginning. Only about 10 percent of drugs tested in Phase 1 go on to make through the FDA, according to a January article in Nature Biotechnology. In fact, more than 100 drugs for Alzheimers disease have either failed in development or been abandoned. Beta amyloid, which OL-1 is meant to lower, was first implicated in the disease at its identification by Alois Alzheimer in 1906. Many researchers believe that the dementia from Alzheimers disease is caused by an accumulation of beta amyloid in the brain, forming plaques that choke healthy cells, leading to the loss of neurons and, eventually, problems with thought. READ MORE Will This Pill Kill Safe Sex? Previous drugs targeting amyloid precursor protein, or APP, have failed. Eli Lilly & Co.s drug to inhibit one of the chemicals that slices APP into beta amyloid not only failed in a final-stage trial, it was worse for patients than a placebo. Another drug company, Myriad, tried a similar route, and also failed in clinical testing. Post Comment Private Reply Ignore Thread
|
||
[Home]
[Headlines]
[Latest Articles]
[Latest Comments]
[Post]
[Sign-in]
[Mail]
[Setup]
[Help]
|